These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
490 related articles for article (PubMed ID: 33239098)
1. Ursodeoxycholic acid and bezafibrate were useful for steroid-refractory, immune-related hepatitis: a case report. Onishi S; Tajika M; Bando H; Matsubara Y; Hosoda W; Muro K; Niwa Y J Med Case Rep; 2020 Nov; 14(1):230. PubMed ID: 33239098 [TBL] [Abstract][Full Text] [Related]
2. Immune-related adverse events in hepatitis treated with thiopurine-based immunosuppressants: A case report. Kawakado K; Nakashima K; Tobita H; Nagase M; Yoshihara K; Horie M; Hamaguchi M; Okimoto T; Tsubata Y; Isobe T Thorac Cancer; 2023 May; 14(13):1208-1211. PubMed ID: 36935519 [TBL] [Abstract][Full Text] [Related]
3. Management of immune-related hepatitis in patients being treated with checkpoint inhibitors for metastatic melanoma, a review and case series. Tew A; Khoja L; Pallan L; Steven N J Oncol Pharm Pract; 2023 Jul; 29(5):1163-1171. PubMed ID: 35607278 [TBL] [Abstract][Full Text] [Related]
4. Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab. Zhang HC; Luo W; Wang Y J Immunother Cancer; 2019 Feb; 7(1):47. PubMed ID: 30777137 [TBL] [Abstract][Full Text] [Related]
5. [Ursodeoxycholic acid combined with bezafibrate in the treatment of refractory primary biliary cholangitis: a meta-analysis]. Feng BL; Yu HH; Shen W Zhonghua Gan Zang Bing Za Zhi; 2019 Apr; 27(4):304-311. PubMed ID: 31082343 [No Abstract] [Full Text] [Related]
7. Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report. Hines J; Daily E; Pham AK; Shea CR; Nadeem U; Husain AN; Stadler WM; Reid P J Med Case Rep; 2021 Mar; 15(1):124. PubMed ID: 33736690 [TBL] [Abstract][Full Text] [Related]
8. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Honda A; Ikegami T; Nakamuta M; Miyazaki T; Iwamoto J; Hirayama T; Saito Y; Takikawa H; Imawari M; Matsuzaki Y Hepatology; 2013 May; 57(5):1931-41. PubMed ID: 22911624 [TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma. Rodriguez EF; Lipson E; Suresh K; Cappelli LC; Monaco SE; Maleki Z Hum Pathol; 2019 Sep; 91():69-76. PubMed ID: 31279873 [TBL] [Abstract][Full Text] [Related]
10. Severe hepatitis arising from ipilimumab administration, following melanoma treatment with nivolumab. Tanaka R; Fujisawa Y; Sae I; Maruyama H; Ito S; Hasegawa N; Sekine I; Fujimoto M Jpn J Clin Oncol; 2017 Feb; 47(2):175-178. PubMed ID: 28173241 [TBL] [Abstract][Full Text] [Related]
11. A Case of Immune Checkpoint Inhibitor Refractory Colitis Treated with Mycophenolate and High-dose Steroids. Alcantar D; Al-Jaashaami L; Giron F Cureus; 2019 Dec; 11(12):e6392. PubMed ID: 31938669 [TBL] [Abstract][Full Text] [Related]
12. Severe steroid refractory gastritis induced by Nivolumab: A case report. Vindum HH; Agnholt JS; Nielsen AWM; Nielsen MB; Schmidt H World J Gastroenterol; 2020 Apr; 26(16):1971-1978. PubMed ID: 32390707 [TBL] [Abstract][Full Text] [Related]
13. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response. Reig A; Sesé P; Parés A Am J Gastroenterol; 2018 Jan; 113(1):49-55. PubMed ID: 29016567 [TBL] [Abstract][Full Text] [Related]
14. IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate. Takano K; Saeki C; Oikawa T; Hidaka A; Mizuno Y; Ishida J; Takakura K; Nakano M; Torisu Y; Amano K; Ishikawa T; Zeniya M; Tsubota A; Saruta M J Gastroenterol Hepatol; 2020 Apr; 35(4):663-672. PubMed ID: 31677185 [TBL] [Abstract][Full Text] [Related]
15. Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncology. Alouani E; Laparra A; Perret A; Sakkal M; Messayke S; Danlos FX; Ouali K; Hollebecque A; Even C; Ammari S; Baldini C; Champiat S; Besse B; Robert C; Guettier C; Samuel D; Lambotte O; De Martin E; Michot JM Eur J Cancer; 2023 Nov; 193():113313. PubMed ID: 37748398 [TBL] [Abstract][Full Text] [Related]
16. Immunotherapy-induced severe neutropenia with neurotoxicity: A case of a 75-year-old woman with ulcerative colitis diagnosed with melanoma. Patel R; Pai L J Oncol Pharm Pract; 2020 Apr; 26(3):730-734. PubMed ID: 31315551 [TBL] [Abstract][Full Text] [Related]
17. Steroid-refractory immune related hepatitis may hide viral re-activation. Citarella F; Galletti A; Russano M; Gallo P; Vespasiani-Gentilucci U; Picardi A; Tonini G; Vincenzi B; Santini D Future Sci OA; 2020 Aug; 6(9):FSO614. PubMed ID: 33235808 [TBL] [Abstract][Full Text] [Related]
18. Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review. Ueno M; Takabatake H; Hata A; Kayahara T; Morimoto Y; Notohara K; Mizuno M Cancer Rep (Hoboken); 2022 Sep; 5(9):e1624. PubMed ID: 35575047 [TBL] [Abstract][Full Text] [Related]
19. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Lens S; Leoz M; Nazal L; Bruguera M; Parés A Liver Int; 2014 Feb; 34(2):197-203. PubMed ID: 23998489 [TBL] [Abstract][Full Text] [Related]
20. Tocilizumab in the treatment of steroid refractory immune-related hepatotoxicity: a case series and review of the literature. Ozluk AA; Gunenc D; Yildirim SS; Karaca B Melanoma Res; 2024 Aug; 34(4):335-342. PubMed ID: 38691011 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]